batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Approval for the world’s twelfth VEGF drug 9 November 2023 Another PI3K inhibitor bites the dust 9 November 2023 More warnings signs for ATR inhibition 9 November 2023 Genmab deals another blow to CD37 8 November 2023 AstraZeneca's phase 3 TIGIT surprise 2 November 2023 Three more Pfizer oncology projects go in latest cull 1 November 2023 Sting’s fortunes wax and wane 1 November 2023 Pfizer enters phase 3 with a CDK4 inhibitor 31 October 2023 Load More